HK Stock Market Move | MEDBOT-B (02252) surged over 6% in early trading, achieving its first semiannual profit. Tumai Siasun Robot & Automation's overseas revenue has increased more than fourfold.

MEDBOT-B (02252) rose over 6% in early trading, up 6.3% as of the time of writing, priced at HKD 22.6, with a transaction volume of HKD 101 million. In terms of news, MicroPort Siasun Robot & Automation recently issued a profit alert, expecting a net profit of RMB 28 million to 40 million for the first half of the year, compared to a loss of RMB 115 million in the same period last year, marking the company's first half-year profit; revenue is expected to grow approximately 200% to 230% year-on-year, estimated at about RMB 527 million to 580 million. The company's key product, TuMai Siasun Robot & Automation, saw overseas revenue growth of over 450%, with overall gross profit margin increasing by more than 15 percentage points. Public information shows that flagship systems such as TuMai and Honghu under MicroPort Siasun Robot & Automation have been approved for market launch in China and the European Union. According to a research report released by DaHua JiXian, MicroPort Siasun Robot & Automation is at the forefront of developing 5G technology-supported remote surgery and integrating AI functionalities to enhance surgical precision and outcomes. Leveraging the extensive global network of its parent company, MICROPORT, it has entered over 60 countries, posing a challenge to major international competitors.